MPO, SAA and sPLA A with Proinflammatory (DL Kaniawati M, et al.) )ndones Biomed J. ; : -DO): . /inabj.v i . Although levels of HDL-C are within normal limit in some patients, they suffer CAD. These normal HDL-C levels might become pro-inflammatoric. This study is to measure the correlations between m yeloperoxidase ( MPO), serum amyloid-A (SAA) p rotein, and secretoryphospholipase-A2 (sPLA2) with inflammatory status of HDL-C.
Not all H DL ( High Density Lipoprotein) p rotect against plaque formation in the arterial walls. This is because in some people HDL was dysfunction, or malformed, and unable to do its job properly. The fact that sometimes HDL doesn't do its job properly can explain why some people who have high HDL levels still get heart attacks and suffer from other cardiovascular disease.
Some researchers found that H DL becomes dysfunction when an enzyme from white blood cells, called myeloperoxidase (MPO), binds to Apo A-1 and modifies it. Once modified, Apo A-1 blocks HDL's ability to perform its normal physiological function. SAA (Serum Amyloid A) is transported in the circulation primarily in association with HDL. SAA levels increase rapidly in the blood of humans suffering from acute and chronic inflammation. SAA has been proved can replace Apo A-1 in HDL in vitro. Because SAA binds to proteoglycans, SAA-containing HDL could bind to extracellular vascular proteoglycans, which would favor the retention and modification of HDL by the vascular matrix. Retention could prevent HDL from participating i n the r everse cholesterol transport and inhibiting oxidative processes in the arterial w all. M odifications o f lipid and p rotein components o f trapped H DL m ight increase its interactions with macrophage scavenger receptors. Rohrer, 2004) sPLA2 (secretory Phospholipase A2) also had a role as atherosclerotic marker and mediator in human. Like SAA, it also can be bound to HDL.
High level of MPO, SAA and sPLA2 can change HDL characteristics from antiinflammatory to proinflammatory, w hich means can change H DL quality. If so, H DL quality actually become more important than HDL quantity.
It might also be that the strategy of increasing HDL levels per se is not enough, and some researchers believe that it is the function oh HDL that needs to be improved rather than its levels (1).  s  t  n  e  t  n  o  c  d  i  p  i  l  s  t  i  y  b  d  e  n  i  m  r  e  t  e  d  e  b  n  a  c  y  t  i  l  a  uL  D  H  (including oxidized lipid) and apolipoprotein in HDL, particle size and electrophoretic m obility, r elated enzymatic activity, inflammatory/antiinflammatory properties and ability to promote cholesterol efflux (2) .
A few studies t o date have investigated the correlation between SAA, sPLA2 and MPO with the change of HDL characteristics from antiinflammatory to proinflammatory. According to that reason, we need to study about the correlation between SAA, sPLA2 and MPO with proatherogenic HDL. Proinflammatory HDL term was used when one of the atheroprotective HDL characteristics was disturbed. Proinflammatory HDL were determined by ApoA-I and hsCRP concentration.
P atients and Methods
Forty nine (49) healthy m ale person with high Cholesterol-HDL ( > 40 mg/dL), aged 33-62 years (man) were enrolled i n this c ross sectional study. Thirty one (31) healthy m ale person with low Cholesterol-HDL (< 40 mg/dL) aged 30-59 years also were analysed. Participants signed informed consents to have personal data such as height, weight, smoking, serum measurements, blood pressure, waist circumference, exercises, alcohol, drugs.
Assays of Biochemical Markers
Serum Amyloid A (SAA) P rotein, secretory Phospholipase A2 (sPLA2) and MPO concentrations were m easured with Enzyme Linked Immuno Assay kit from Anogen, Cayman, and Calbiochem respectively. Serum were separated from whole blood after centrifugation, and immediately kept at -20oC until assays. All assays were performed according to manufacturers instruction.
For each run of SAA Protein, sPLA2 and MPO, controls were included in the assays, and all results were within acceptable ranges. In our laboratory, the intraday imprecisions for all assays were between 4.2% -5.4%. SAA = Serum Amyloid A; sPLA2 = secretory Phospholipase A2; MPO = Myeloperoxidase; hs-CRP = high sensitivity C-Reactive Protein HDL-C was defined as proinflammatory based on levels Apo A-1 < 125 mg/dL, and or hs-CRP > 1,1 mg/L. From 49 subjects with high HDL-C (> 40 mg/dL), by using that criteria we found 28 subjects with antiinflammatory properties and 2 1 subjects w ith p roinflammatory p roperties. S tatistical analysis w as m ade u sing independent sample t test to see the different between SAA, sPLA2 and MPO. 
Discussions
Normally, HDL exert a range of potent biological activities that p rovide p rotection against atherosclerosis. These actions include a key r ole in m ediating cholesterol efflux f rom plaque macrophages and foam cells, and from peripheral tissues, w ith transport t o the liver for excretion via the p rocess o f reverse cholesterol transport; equally, anti-oxidant, anti-inflammatory, antiapoptotic, anti-thrombotic, anti-infectious and vasodilatory properties are central features of HDLmediated atheroprotection. HDL particles are highly heterogeneous in terms of their physico-chemical characteristics, structure, intravascular metabolism and biological activity.
The r ole of H DL i n atherosclerosis i s not apart from the role of Apo A-1. Apo A-1 ability to promote reverse cholesterol transport and remove seeding molecule from LDL (important in oxidized phospholipids formation, originate from L DL inflammatory) contribute t o inverse relationship between HDL-cholesterol level and susceptibility to atherosclerosis (3).
HDL can bind and neutralize lipopolysaccharide, to m odulate acute and c hronic inflammation. Flowcytometry analysis shows that Apo A-1 associated with HDL can inhibit monocyte activation by binding to T lymphocyte, to inhibit tumor necrosis factor (TNF)-and interleukin-1 production, essential component on immunoinflammatory diseases pathogenesis. It has been hypothesised that increasing HDL have an effect on antiinflammation action (5) .
In this study, subject were divided into high HDL group (HDL > 40 mg/dL, n = 49) and low HDL group (HDL < 40 mg/dL, n = 31). Based on median of Apo A-1 (125 mg/dL) and hs-CRP (1,1 mg/L) we determined HDL antiinflammatory type if the subject has A po A-1 > 125 mg/dL and/or has hs-CRP < 1,1 mg/L, and HDL proinflammatory if the subject has Apo A-1 < 125 mg/dL and/or has hs-CRP > 1,1 mg/L. From 49 subjects with high HDL we found 28 subject with HDL antiinflammatory type and 21 subjects with HDL proinflammatory. From subjects with low HDL we found only 1 subject with HDL anti-inflammatory type and 30 subjects with HDL proinflammatory type. 
o (57,14%), 25 subjects with high sPLA2 ( 51,02%) and 22 subjects with high MPO (44,90%). Possibly because there is big relationship with the finding of HDL proinflammatory in high HDL group. In some subjects with high HDL level (formerly thought to be protective) when accompanied by high MPO, and/or high SAA, and/or high sPLA2, the HDL function will be disturbed, that shown by low Apo A-1 and/or high hs-CRP.
From our study we found :
-there was significant positive correlation between SAA with HDL proinflammatory, with prevalence ratio 10,800, p = 0,001. -there w as weak positive correlation between sPLA2 w ith H DL p roinflammatory, p revalence ratio 1,100, p = 0,869.
-SAA is the best independent p redictor by multivariate logistic r egression analysis wit h prevalence ratio 11,744 ; p = 0,002, followed by MPO and sPLA2.
Interaction between SAA, sPLA2 and MPO in HDL proinlammatory
Several epidemiological studies showed inverse relationship between HDL and artery coroner disease risk.
Part of HDL protective effect is caused by LDL oxidative modiication inhibition or by promoting cholesterol eflux from pheriferal cells. In certain condition, eg.
acute phase reactant, native antioxidant properties of HDL were changed. Just the opposite from native HDL that inhibit LDL modiication and monocyte adhesion to endothelial cells in artery cocultur system, acute phase-HDL will increase monocyte adhesion. In acute phase, lipoprotein composition change dramatically from non acute phase condition. In this condition, HDL showed big increasing SAA, with decreasing Apo A-1 level. HDLcontaining Apo A-1 particle consist of lecithin cholesteryl acyl transferase (LCAT), that responsible for plasma cholesterol esteriication and acting as HDL ligand that has role in HDL interaction with cell. Apo A-1 substitution by SAA within acute phase can inhibit LCAT activity in HDL, repressing cholesterol eflux from pheriferal cells (6) .
Recent study has evaluated HDL protective effect. HDL-enriched with SAA does not have protective effect.
This study suggested that within acute phase, joining SAA into HDL can cause changing in HDL particle, and diminished protective capacity to LDL oxidation. Acute phase-HDL is not only inhibit LDL oxidation but also result in monocyte migration (6) .
In our study, we found 28 person (57,14%) who has high level of SAA in high HDL group. By using univariate logistic regression analysis we found that in high HDL group, SAA is the best independent predictor with prevalence ratio 10,800 (95% CI : 2,543 -45,866), p : 0,001, on the other hand based on multivariate regression analysis shown that in high HDL group SAA is still best independent predictor with prevalence ratio 11,744 (95% CI : 2,515 -54,839) p : 0,002, followed by MPO and sPLA2 respectively. It means that serum SAA level is signiicantly associated and independent with proinlammatory HDL type.
This result similar with van Lenten inding. They found decreasing 73% Apo A-1 level in people with high SAA level. People with high level of HDL, if accompanied by high SAA can have proinlammatory HDL type.
Secretory Phospholipase A2 (sPLA2) is an enzyme that break acyl ester in sn-2 position in glycerophospholipid when activated. sPLA2 is extracellular enzyme with high disulphide binding, with low molecular weight (14 KDa), and need mM Ca2+ for catalysis. This enzyme has important role in arachidonic and eicosanoid formation, proinlammatory mediator. PLA2 has several biological action such as immunologic respons, inlammation, cellular proliferation, vasoconstriction and bronchioconstriction.
Circulating sPLA2 level will increase dramatically within infection and inlammation. In nonatherosclerotic artery, sPLA2 type IIA especially associated with smooth muscle cells. In atherosclerotic lesion, this enzyme associated with macrophage, necrotic lipid core and extracellular vascular proteoglican. This enzyme was bound with very high afinity (7).
Our study found 25 person (51%) who has high sPLA2 in high HDL group. Based on univariate logistic regression analysis sPLA2 was not proven associated signiicantly with proinlammatory HDL type. This is not similar with former reports that mention that in person with high HDL level, if accompany by high sPLA2, his HDL will change to proinlammatory type.
There are several possibilities as a cause for these differences. First, there are some steps in the testing procedure that should be paid attention. The higher standard to achieve standard curve is 1.000 pg/mL, and our results are in the range 293 to 2.696 pg/mL. Mean + SD : 1340,18 + 406,27 pg/mL. Diluting factor is very important if we want to continue this research. Second, absorbance reading also can be done several times (15, 30, 60, 120, 240, 360 minutes). In our research, we used value only at 15 and 30 minutes reading, and we calculate the difference. Perhaps, this reading method inluence the value. Third, we used sPLA2 (human Type IIa) EIA kit that measure sPLA2 concentration.
Maybe it will be better to use kit that measure sPLA2 activity, because measurement of enzyme activity generally has better correlation than measuring the concentration. Fourth, the number of research sample too small so it is not enough to prove the double hypothesis in this research. Fifth, the recent researchs usually predict the correlation between high sPLA2 with proinlammatory properties of low HDL. We want to know wheter the inluence of this high sPLA2 can happen in high HDL group with proinlammatory properties. Our analysis shown that sPLA2 mean in high HDL group with proinlammatory properties higher than sPLA2 mean in low HDL group. Possibly sPLA2 can inluence to change HDL properties, from anti-inlammatory to proinlammatory, but this effect need long time to occur.
Modiication by MPO product, can cause Apo A-1 bind tightly to the artery. Similarly with the inding in Fogelman study that in atherosclerosis artery, we can ind Apo A-1 in a big amount. In a non modiied-Apo A-1, on the contrary, the normal Apo A-1 doesn't have binding site with heparin. So we can ind more Apo A-1 in plasma than in artery (8) . Level of hs-CRP > 3 mg/L will strengthen the prediction about inlammation and showing the risk to get cardiovascular disturbances in the future if doesn't treat earlier.
Even oxidation product by MPO can be found more abundant in circulation HDL in individu with CVD and atherosclerosis lesion, in fact signiicant amount also can be found in Apo A-1 from the healthy individual serum (9).
We found 22 individu (44,9%) with high MPO in high HDL group. Based on univariate logistic regression analysis, the prevalence ratio is 0,865 (95% CI : 0,277 -2,705) with p = 0,804. With multivariate logistic regression analysis, the prevalence ratio is 1,265 (95% CI: 0,304 -5,272) with p = 0,747. It means that MPO doesn't have signiicant association with proinlammatory-HDL. It is different with the previous studies which show that in individu with high HDL accompany by high MPO, the HDL become proinlammatory HDL.
There are some possibilities as the cause of this differences. First, Apo A-1 oxidation catalyzed by MPO in arterial wall or in circulation, not followed by selective deposition of modiied lipoprotein in arterial wall, so Apo A-1 still can be measured in the blood. Besides, we must remember that -different from LDL that has only one Apo B on its each particle-more than one Apo A-1 can be found on each HDL particle. This )ndones Biomed J.
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deposition issue was still a question mark for previous researchers and has not yet been answered by existing studies. Factors that influence the modified Apo A-1 deposition in the artery wall have to be found out. Second, the process of Apo A-1 modification progress slowly that it takes quite a long time to be able to alter the HDL function to become pro-inflammatory. Other studies using the case control or cohort designs are probably needed. Subjects with elevated MPO can be reexamined at another time for the HDL type, to see if there is any change to pro-inflammatory HDL. Third, to get a better understanding about the proinflammatory HDL, w e indeed need to m easure not only the Apo A-1 concentration, but also the 3-chlorotyrosine in HDL using mass spectrophotometry. Increased 3-chlorotyrosine in HDL indicated high level of Apo A-1 modification by MPO (10).
Relationship between Study Results and Epidemiological Data
Recently, several reports had given a number of data supporting the statement o f the involvement of M PO in H DL p ro-inflammatory characteristics. This is suggested to associate with the MPO ability (through its products) to modify Apo A-1. When Apo A-1 is modified by MPO, it will block the normal HDL function. There is an inverse relationship between the amount of tyrosine in apoA-I modified by MPOderived products and the ability of HDL to remove cholesterol from macrophages. Thus, the more tyrosine in apoA-I that is modified by MPO-derived products, the less effective the HDL is in removing cholesterol. Modified Apo A-1 will tightly bind the artery wall, unlike the unmodified Apo A-1. Our study revealed different thing. In group with HDL ≥ 40 mg/dL, we found weak correlation between MPO activity with the Apo A-1 concentration in blood (r = 0.250; p = 0.083). Besides, MPO activity also had very weak correlation with hs-CRP (r = 0.140; p = 0.315), and unsurprisingly, the univariate or multivariate regression analysis of MPO did not show significant association with HDL type. MPO is not a strong indicator for the change of HDL characteristics from anti-inflammatory to proinflammatory. From this study, we found that SAA concentration in group with HDL ≥ 40 mg/dL had weak correlation with Apo A-1 concentration in blood (r = 0.261; p = 0.070), but had strong correlation with hs-CRP (r = 0,453*; p = 0.005). Based on previous reports by other researchers, the decrease in plasma Apo A-1 levels with induction of the acute phase response has been attributed to displacement of Apo A-1 from HDL particle with SAA in vivo and in in vitro (11) . The real mechanism of the displacement of Apo A-1 with SAA, has not been known until now. This study also showed that in the group with H DL ≥ 40 mg/dL, the concentration of sPLA2 correlated weakly with the concentration of Apo A-1 in blood samples (r= -0.303*; p = 0.034). In the meantime, the concentration of sPLA2 had strong correlation with increased hs-CRP (r=0.503*; p=0.000). This finding was probably because we measured the concentration of the enzymes of sPLA2, and not directly the sPLA2 activity, and high concentration may not always mean high activity. The activity of sPLA2 in hydrolyzing phospholipids can release oxidized fatty acid from lipoprotein including HDL, which is pro-inflammatory and pro-atherogenic. The research by Rohrer showed a high concentration of CRP in elevated sPLA2 (12) .
Relationship between H DL level and c ardiovascular disease has been widely known. Low HDL level is related to high risk of CVD. In our study, 44.9% of individual with elevated HDL (considered protective) found to have high MPO, 51% had high sPLA2 and 57.14% had high SAA. On the whole, 87.8% of individual with elevated HDL level had high MPO and/or high sPLA2 and/or high SAA. Looking at the result of this study, it is appropriate if these markers are also observed at the time of performing other cardiovascular risk factors tests. The next thing is the estimation of the effect of MPO, sPLA2 and SAA on HDL function.
Association between SAA, sPLA2, MPO and the forming of pro-inflammatory HDL is very likely to be influenced by factor of time, how long the HDL is exposed with those three factors. In our study, SAA factor had better correlation with HDL than sPLA2 and MPO.
Cause-Effect Relationship in Study Variables
Interaction between the concentration of MPO, sPLA2 and SAA with pro-inflammatory HDL indicated that SAA was involved in HDL characteristics change from anti-inflammatory t o pro-inflammatory, w hich was indicated with Apo A-1 level < 125 mg/dL and/or hs-CRP > 1.1 mg/L. This is suggested to be related to increasing in atherosclerosis risk. Thus, when early intervention can b e done either b y life style m odification or therapeutic treatment which is intended to reduce this risk, the change of HDL characteristics from antiinflammatory t o pro-inflammatory can indeed be
